CD33-TIM3 pooled CAR T cells

CD33-TIM3 pooled CAR T cells is a preclinical-stage, dual-targeting chimeric antigen receptor (CAR) T-cell therapy being investigated for the treatment of acute myeloid leukemia (AML). The therapy utilizes a 'pooled' approach, which involves a mixture of two distinct T-cell populations: one targeting the myeloid-associated antigen CD33 (using an scFv derived from the hP67.6 clone) and another targeting T-cell immunoglobulin and mucin-domain containing-3 (TIM3). CD33 is expressed in the majority of AML cases, while TIM3 is a marker for leukemic stem cells (LSCs) and is notably absent on healthy hematopoietic stem and progenitor cells (HSPCs). This dual-targeting strategy is designed to enhance anti-tumor efficacy through increased avidity and cytotoxicity while minimizing off-tumor toxicity to healthy bone marrow. Developed by researchers at LMU Munich, the construct has shown promising results in in vitro assays and NSG mouse models, as reported at the ASH 2023 annual meeting.

Other names

CD33-TIM3 dual CAR T cellsCD-33-TIM3 dual CAR T cellsCD 33-TIM3 dual CAR T cells